HENDERSON, Nev., Nov. 29, 2017 — United Health Products, Inc. (UHP) (OTC:UEEC), a manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that its South African distributor, SSEM Mthembu Medical (SSEM), has notified UHP that they have approved HemoStyp to be marketed in South Africa. SSEM has placed its first order for the product with UHP.
The approval is for applications for wounds that have breached the dermis and where the wounds can only heal by secondary intent. The applications include severe wounds that have extensively breached the dermis, and healing is by secondary intent (by granulation from the base of the wound). Examples: dressings for chronic extensive ulcerated wounds, severe burns, severe decubitus wounds, or dressings providing a temporary skin substitute.SSEM Mthembu Medical (Pty) Ltd. is a distributor of electro-medical devices and medical consumables throughout Southern Africa.SSEM Mthembu Medical provides specialised equipment to meet the stringent expectations of specialist physicians, private clinics and hospitals – including operating theatres, critical care, high care units, trauma and emergency care. The company also caters for the occupational health and home care sectors.About United Health Products, Inc.United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.comSafe Harbor StatementSafe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Powered by WPeMatico